Spencer Chapman, Michael http://orcid.org/0000-0002-5320-8193
Cull, Alyssa H.
Ciuculescu, Marioara F.
Esrick, Erica B.
Mitchell, Emily
Jung, Hyunchul
O’Neill, Laura
Roberts, Kirsty
Fabre, Margarete A.
Williams, Nicholas
Nangalia, Jyoti http://orcid.org/0000-0001-7122-4608
Quinton, Joanne
Fox, James M.
Pellin, Danilo http://orcid.org/0000-0002-2647-0508
Makani, Julie
Armant, Myriam http://orcid.org/0000-0002-5205-3003
Williams, David A. http://orcid.org/0000-0001-7057-6863
Campbell, Peter J. http://orcid.org/0000-0002-3921-0510
Kent, David G. http://orcid.org/0000-0001-7871-8811
Article History
Received: 19 May 2023
Accepted: 10 October 2023
First Online: 16 November 2023
Competing interests
: P.J.C. is a co-founder, stockholder and consultant for FL86. M.A.F. is an employee and stockholder of AstraZeneca. D.G.K. receives laboratory funding from STRM.bio. D.A.W. serves on the following committees: Novartis steering committee, Beam Therapeutics scientific advisory board, Skyline Therapeutics (formerly Geneception) scientific advisory board and Biomarin insertion site advisor board. D.A.W. also acts as a consultant for Verve Therapeutics and Monte Rosa Therapeutics. He also has research funding from ExCellThera. E.B.E. served as a consultant for a bluebird bio steering committee. The remaining authors declare no competing interests.